Halozyme Therapeutics (HALO) announced the appointment of Darren Snellgrove as CFO, effective June 8. Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and CEO. Snellgrove brings more than 30 years of exceptional financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson (JNJ). In that role, he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Appoints New Chief Financial Officer to Drive Growth
- Halozyme price target raised to $95 from $90 at H.C. Wainwright
- Halozyme price target raised to $96 from $94 at Morgan Stanley
- Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
- Halozyme enters global global collaboration and license agreement with Vertex